Literature DB >> 19430819

GP-led melanoma follow-up: views and feelings of patient recipients.

Peter Murchie1, Elizabeth K Delaney, Neil C Campbell, Philip C Hannaford.   

Abstract

OBJECTIVES: The aim of this study was to explore the practical experiences and feelings of people with cutaneous malignant melanoma about receiving structured melanoma follow-up from their general practitioner (GP) as an alternative to traditional hospital-based follow-up.
DESIGN: Semi-structured audio-taped telephone interviews were conducted with patient recipients of a GP-led follow-up programme for people with cutaneous malignant melanoma.
SUBJECTS: Eighteen people with cutaneous malignant melanoma that had received structured GP-led routine follow-up for cutaneous malignant melanoma took part in this study.
RESULTS: GP-led melanoma follow-up worked well from the perspectives patients. Patients appreciated convenience of the system, less rushed appointments with more thorough examinations, a more pleasant atmosphere and greater continuity of care. They regarded the GP-led follow-up positively, irrespective of distance from the major cancer centre. Concerns expressed included awareness that most GPs had less experience of melanoma than hospital specialists.
CONCLUSIONS: GP-led melanoma follow-up is feasible and is generally viewed positively by those patients that have experienced it.

Entities:  

Mesh:

Year:  2009        PMID: 19430819     DOI: 10.1007/s00520-009-0648-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  12 in total

1.  Lost in translation: the value of qualitative data.

Authors:  David Lanier
Journal:  J Am Board Fam Pract       Date:  2005 Sep-Oct

2.  Views of UK melanoma patients on routine follow-up care.

Authors:  A Dancey; S Rayatt; J Courthold; J Roberts
Journal:  Br J Plast Surg       Date:  2005-03

3.  The experience of long-term hospital follow-up for women who have suffered early stage gynecological cancer: a qualitative interview study.

Authors:  E.J. Bradley; M.K. Pitts; C.W.E. Redman; E. Calvert
Journal:  Int J Gynecol Cancer       Date:  1999-11       Impact factor: 3.437

4.  Running nurse-led secondary prevention clinics for coronary heart disease in primary care: qualitative study of health professionals' perspectives.

Authors:  Peter Murchie; Neil C Campbell; Lewis D Ritchie; Joan Thain
Journal:  Br J Gen Pract       Date:  2005-07       Impact factor: 5.386

5.  Follow up in breast cancer. Patients prefer specialist follow up.

Authors:  J Maher; J Bradburn; R Adewuyi-Dalton
Journal:  BMJ       Date:  1995-07-01

6.  Preferences for follow-up after treatment for lung cancer: assessing the nurse-led option.

Authors:  Karen Cox; Eleanor Wilson; Lesley Heath; Jacqueline Collier; Linda Jones; Ian Johnston
Journal:  Cancer Nurs       Date:  2006 May-Jun       Impact factor: 2.592

7.  Satisfaction with routine follow-up visits to the physician--the needs of patients with breast cancer.

Authors:  I Koinberg; L Holmberg; B Fridlund
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

8.  Patients' views of routine hospital follow-up: a qualitative study of women with breast cancer in remission.

Authors:  R Adewuyi-Dalton; S Ziebland; E Grunfeld; A Hall
Journal:  Psychooncology       Date:  1998 Sep-Oct       Impact factor: 3.894

9.  Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health.

Authors:  Peter Murchie; Philip C Hannaford; Sally Wyke; Marianne C Nicolson; Neil C Campbell
Journal:  Fam Pract       Date:  2007-04-21       Impact factor: 2.267

10.  Breast cancer patients' satisfaction with a spontaneous system of check-up visits to a specialist nurse.

Authors:  Inga-Lill Koinberg; Lars Holmberg; Bengt Fridlund
Journal:  Scand J Caring Sci       Date:  2002-09
View more
  7 in total

Review 1.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

2.  Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial.

Authors:  P Murchie; M C Nicolson; P C Hannaford; E A Raja; A J Lee; N C Campbell
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 3.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

4.  What do patients and dermatologists prefer regarding low-risk basal cell carcinoma follow-up care? A discrete choice experiment.

Authors:  Sven van Egmond; Esther de Vries; Loes Hollestein; Maarten Bastiaens; Kees-Peter de Roos; Daniëlle Kuijpers; Ewout Steyerberg; Marlies Wakkee; Klara Mosterd; Tamar Nijsten; Esther W de Bekker-Grob
Journal:  PLoS One       Date:  2021-03-29       Impact factor: 3.240

5.  Healthcare practices that increase the quality of care in cancer trajectories from a general practice perspective: a scoping review.

Authors:  Anne Nicolaisen; Gitte Bruun Lauridsen; Peter Haastrup; Dorte Gilså Hansen; Dorte Ejg Jarbøl
Journal:  Scand J Prim Health Care       Date:  2022-03-07       Impact factor: 3.147

6.  Factors influencing the translation of shared cancer follow-up care into clinical practice: a systematic review.

Authors:  Tiffany Sandell; Heike Schütze
Journal:  BMJ Open       Date:  2022-08-29       Impact factor: 3.006

7.  Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care.

Authors:  Lucie Rychetnik; Rachael L Morton; Kirsten McCaffery; John F Thompson; Scott W Menzies; Les Irwig
Journal:  BMC Health Serv Res       Date:  2012-12-19       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.